China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHA:600062)
China · Delayed Price · Currency is CNY 19.04
-0.02 (-0.10%)
Sep 18, 2025, 11:29 AM CST
SHA:600062 Revenue
China Resources Double-Crane Pharmaceutical had revenue of 2.66B CNY in the quarter ending June 30, 2025, a decrease of -4.36%. This brings the company's revenue in the last twelve months to 11.02B, down -3.26% year-over-year. In the year 2024, China Resources Double-Crane Pharmaceutical had annual revenue of 11.21B, down -0.87%.
Revenue (ttm)
11.02B
Revenue Growth
-3.26%
P/S Ratio
1.78
Revenue / Employee
821.83K
Employees
13,414
Market Cap
19.58B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.21B | -98.52M | -0.87% |
| Dec 31, 2023 | 11.31B | 1.68B | 17.50% |
| Dec 31, 2022 | 9.63B | 513.80M | 5.64% |
| Dec 31, 2021 | 9.11B | 607.58M | 7.14% |
| Dec 31, 2020 | 8.50B | -877.05M | -9.35% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jiangsu Hengrui Medicine | 30.15B |
| WuXi AppTec | 41.90B |
| Shenzhen Mindray Bio-Medical Electronics | 32.94B |
| Sichuan Biokin Pharmaceutical | 441.19M |
| Shanghai United Imaging Healthcare | 10.98B |
| Zhangzhou Pientzehuang Pharmaceutical., | 10.52B |
| Aier Eye Hospital Group | 21.94B |
| Yunnan Baiyao Group Co.,Ltd | 40.84B |